SCHEMBL10153133

SCHEMBL10153133

Cc1nc(C(=O)O)c(C)n1-c1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
SLC6A4 P31645 1/20 0.46
DPP4 P27487 1/20 0.45
MYC P01106 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
ALKBH2 Q6NS38 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42
KDM4E B2RXH2 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.40
CNR1 P21554 3/20 0.40
CNR2 P34972 3/20 0.40
LMNA P02545 1/20 0.40
NAPRT Q6XQN6 1/20 0.40
P4HTM Q9NXG6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083616 0.98 ALDH1A1 (0.47) ALDH1A1HTR2AHTR2CSLC6A4DPP4
Lithium Ion SCHEMBL1083615 0.85 HTR2A (0.45) ALDH1A1HTR2AHTR2CSLC6A4DPP4
SCHEMBL1077879 0.82 HPGD (0.50) ALDH1A1HTR2AHTR2CSLC6A4SMN1; SMN2
SCHEMBL3684239 0.79 CNR1 (0.57) ALDH1A1SMN1; SMN2MEN1MAPTKMT2A
SCHEMBL1078089 0.78 CNR1 (0.56) ALDH1A1SMN1; SMN2MEN1MAPTKMT2A
SCHEMBL4436267 0.76 CNR1 (0.52) CNR1CNR2
SCHEMBL7589888 0.76 SMN1; SMN2 (0.49) ALDH1A1HTR2AHTR2CSLC6A4DPP4
SCHEMBL10153088 0.74 SORD (0.41) ALDH1A1HTR2AHTR2CSLC6A4DPP4
SCHEMBL23130829 0.73 HTT (0.65) ALDH1A1MYCSMN1; SMN2ALKBH2EGLN1
SCHEMBL16935876 0.73 HCAR1 (0.47) MYCPOLBCNR1CNR2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835436-B2 Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2014-09-16 US disclosed
US-8835436-B2 Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2014-09-16 US disclosed
US-20120115881-A1 NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115881-A1 NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HTR2C, HTR5A, HTR2A ALDH1A1 667/4885HTR2A 3/4885HTR2C 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.